Esophageal cancer
MONDO:0007576A primary or metastatic malignant neoplasm involving the esophagus.
Also known as: cancer of esophagus, cancer of oesophagus, esophageal cancer, esophageal cancer, somatic, esophageal carcinoma, somatic, esophageal squamous cell carcinoma, somatic, esophagus cancer, malignant esophageal neoplasm
3587 clinical trials for this condition and its sub-types, 408 tagged with Esophageal cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Esophageal cancer
-
Carcinoma of esophagus 76 trials · 509 incl. sub-types
5 sub-types
- Esophageal squamous cell carcinoma 306 trials · 307 incl. sub-types Sub-types →
- Esophageal adenocarcinoma 170 trials · 174 incl. sub-types Sub-types →
- Esophagus carcinoma in situ 13 trials
- Esophageal small cell neuroendocrine carcinoma 2 trials
- Carcinoma of esophagus, salivary gland type 0 trials
-
Esophageal melanoma 1 trial
-
Esophagus lymphoma 0 trials
-
Esophagus sarcoma 0 trials
2 sub-types
- Esophagus leiomyosarcoma 0 trials
- Esophagus liposarcoma 0 trials
Most studied deeper sub-types
-
Can a new drug combo revive Immunotherapy's power against resistant tumors?
Disease control Stopped earlyThis trial is testing whether an experimental drug called NC410, when combined with the immunotherapy drug pembrolizumab, can safely and effectively treat people with advanced solid tumors that have not responded to standard immunotherapy or that are unlikely to respond. The stud…
Phase 1/2 • Sponsor: NextCure, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug combos aim to boost survival in Hard-to-Treat cancers
Disease control Stopped earlyThis study tested several immunotherapy-based drug combinations in 214 people with advanced stomach, gastroesophageal junction, or esophageal cancer that could not be removed by surgery or had spread. Participants received either standard chemotherapy or chemotherapy plus the imm…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Immune cell rescue after radiation shows promise in early cancer trial
Disease control Stopped earlyThis study tested whether giving patients their own immune cells (called lymphocytes) after chemotherapy and radiation could help their immune system recover faster. It included 19 adults with lung or esophageal cancer. The treatment was designed to reduce a common side effect of…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Cancer combo trial halted early: what we learned
Disease control Stopped earlyThis study tested a combination of two drugs, donafenib and KN046, in people with advanced gastrointestinal cancers that had not responded to standard treatments. The goal was to check safety and see if the drugs could shrink tumors. The trial was stopped early, and only 15 peopl…
Phase 1/2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental cancer drug AUR106 tested in humans for first time
Disease control Stopped earlyThis early-stage trial tested an experimental drug called AUR106 in 21 adults with advanced solid tumors (lung, stomach, bladder, kidney, colon, or esophageal cancer) that had come back or spread. The main goals were to check safety, find the right dose, and see how the drug move…
Phase 1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Early trial of PF-08046031 for advanced cancers ends early
Disease control Stopped earlyThis early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or had no standard treatment options. The main goal was to check the drug's safety and side effects. The trial was terminated early, so its findin…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Engineered immune cells take on Hard-to-Treat gut cancers
Disease control Stopped earlyThis early-phase study tested a new treatment called LCAR-G08, which uses a patient's own immune cells (T-cells) that are modified in a lab to recognize and attack cancer cells in the gut. The study included 17 adults with advanced colorectal, stomach, pancreatic, or small bowel …
Phase 1 • Sponsor: Peking University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Promising combo for rare cancer mutation stalls as study ends early
Disease control Stopped earlyThis early-phase study tested a new drug called PRT3789 combined with the immunotherapy pembrolizumab (Keytruda) in people with advanced solid tumors that have a SMARCA4 gene mutation. The goal was to see if the combination was safe and could shrink tumors. However, the study was…
Phase 2 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients – study halted early
Disease control Stopped earlyThis early-phase trial tested an experimental drug called TAK-500, alone or with the immunotherapy pembrolizumab, in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The stud…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Targeted drug shows promise for rare genetic cancers
Disease control Stopped earlyThis study tested a drug called niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific genetic change called a PALB2 mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stoppe…
Phase 2 • Sponsor: Tempus AI • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental cancer drug INCB062079 tested in early trial
Disease control Stopped earlyThis early-phase trial tested a new drug called INCB062079 in 25 people with advanced liver cancer and other solid tumors. The main goal was to check safety and find the best dose. The study was terminated early, so results are limited.
Phase 1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Robotic surgery for esophageal cancer: a gentler approach?
Disease control Stopped earlyThis trial compared a newer, robotic-assisted minimally invasive surgery (RAMIE) to the standard open surgery for esophageal cancer. The goal was to see if it's possible to run a larger study comparing the two approaches. The study enrolled 24 adults with stage I-III esophageal c…
Sponsor: St. Joseph's Healthcare Hamilton • Aim: Disease control
Last updated Jun 26, 2026 17:56 UTC
-
AI reads scans to spot esophageal cancer and predicts best treatment path
Diagnosis Stopped earlyThis study tests two AI models that analyze endoscopy and CT images to diagnose esophageal cancer and predict how deep the tumor has grown. The goal is to help doctors decide if a patient can be treated with a less invasive endoscopic procedure or needs more aggressive therapy. T…
Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
New scan may reveal if cancer treatment is working
Knowledge-focused Stopped earlyThis study is testing whether a special PET scan called 18F-FSPG can help doctors see how well chemotherapy and radiation are working in people with esophageal cancer. Nine adults with untreated, locally advanced esophageal cancer will get the scan before and during treatment. Th…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can 3D motion capture reveal hidden breathing problems after esophageal cancer surgery?
Knowledge-focused Stopped earlyThis study investigates how chest wall movement and lung function change in people who had open surgery for esophageal cancer more than a year ago, compared to healthy volunteers. Researchers use a 3D motion capture system and wearable sensors to track chest movement during breat…
Sponsor: Imperial College London • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Feeding delay after esophageal surgery studied for muscle preservation
Knowledge-focused Stopped earlyThis study aimed to see if delaying feeding for a few days after esophageal cancer surgery helps protect muscle mass and improve recovery. It included 239 adults with esophageal cancer who were scheduled for surgery. The study was stopped early, so results are limited.
Sponsor: University Hospital, Gasthuisberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer gene hunt: could tumor maps guide better GI cancer treatment?
Knowledge-focused Stopped earlyThis study looked at genetic mutations in tumors from 565 people with advanced gastrointestinal cancers, including liver, bile duct, gallbladder, pancreas, esophagus, and stomach cancers. The goal was to see how often these mutations could be targeted by existing drugs and to tra…
Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC